// App-Quantinova.ai

TPS2606 : NCI-MATCH (Molecular Analysis for Therapy Choice) a national signal finding trial.

Researchers

Presenter

  • Barbara A. Conley

Principal Investigators

  • Alice P. Chen

  • Peter J. O'Dwyer

  • Carlos L. Arteaga

  • Stanley R. Hamilton

  • Paul M. Williams

  • Richard F. Little

  • Naoko Takebe

  • David Patton

  • Kamalia Sazali

  • Jeffrey Zhang

  • James A. Zwiebel

  • Edith P. Mitchell

  • Robert James Gray

  • Lisa McShane

  • Shuli Li

  • Larry Rubinstein

  • Keith Flaherty

Medical Centers

  • National Cancer Institute, Rockville, MD

  • Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Leidos, Frederick, MD

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

  • National Cancer Institute at the National Institutes of Health, Rockville, MD

  • National Cancer Institute/Center for Biomedical Informatics & Information Technology, Rockville, MD

  • ECOG-ACRIN Cancer Research Group, Boston, MA

  • Cancer Therapy Evaluation Program, Bethesda, MD

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • National Cancer Institute, Bethesda, MD

  • Biometric Research Program, OD, Division of Cancer Treatment and Diagnosis, Bethesda, MD

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Anaplastic lymphoma Kinase

  • Neurotrophic tropomyosin receptor kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Patched 1

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Proto-oncogene tyrosine-protein kinase ROS

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • Fibroblast growth factor receptor

  • GTPase Nras

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Neurofibromatosis type 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02465060

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved